Applied Biosystems Group and Celera Genomics Group Fourth Quarter and Year-End FY 2002 Financial Results and Conference Call Scheduled for July 25, 2002
Norwalk, CT - July 11, 2002
Applera Corporation announced today that it will issue fiscal year 2002 fourth quarter and full year results for Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA) on Thursday, July 25, 2002. Results are scheduled for release before the opening of trading on the New York Stock Exchange.
Tony L. White, Applera Corporation's chief executive officer, will lead a conference call at 10:00 a.m. (EDT) on July 25 to discuss these results and to address management's current financial outlook for the company. He will be joined by Dennis L. Winger, Applera's chief financial officer, and senior managers from the Corporation’s business units. After making prepared remarks, the management team will answer questions from securities analysts and investment professionals. Investors, securities analysts, representatives of the media and international participants who would like to participate should dial 706.634.4992 (code "Applera") between 9:45 and 10:00 a.m. This conference call will also be webcast. Interested parties who wish to listen to the webcast should visit either www.applera.com and go to the “Investor Relations” section of the web site, or www.celera.com and go to the “Investor” section, or www.appliedbiosystems.com and go to the Investor Relations web page within the "About Us" section. A digital recording will be available two hours after the completion of the conference call from July 25 to August 3, 2002. Interested parties should call 706.645.9291 and enter Conference ID 4347065.
About Applera Corporation
Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to market scientific discoveries, leading to the development of new pharmaceuticals, and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its genomic and proteomic technology platforms to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. Its Celera Discovery System™ online platform, marketed exclusively through the Knowledge Business of Applied Biosystems, is an integrated source of information based on the human genome and other biological and medical sources. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.